[HTML][HTML] Managing high-risk atrial fibrillation patients with multiple comorbidities
GYH Lip - International Journal of Arrhythmia, 2023 - Springer
Atrial fibrillation (AF) patients are often high risk being elderly and having multiple
comorbidities. Many risk factors are established to be associated with new onset incident AF …
comorbidities. Many risk factors are established to be associated with new onset incident AF …
[PDF][PDF] Comprehensive systematic review and meta-analysis on anticoagulants and aspirin for stroke prevention in non-valvular atrial fibrillation patients.
ZQ Xu, ZH Xu, N Zhang - European Review for Medical & …, 2023 - europeanreview.org
OBJECTIVE: Non-valvular atrial fibrillation (NVAF) is a common manifestation of cardiac
arrhythmia, whose significance is heightened in the context of an aging global population …
arrhythmia, whose significance is heightened in the context of an aging global population …
Payer formulary exclusions of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, A Kang… - Current Medical …, 2022 - Taylor & Francis
In recent years, US payers have increased usage of formulary exclusions as a means to
help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the …
help manage costs. Earlier this year, one of the largest pharmacy benefit managers in the …
Payer formulary tier increases of apixaban: how patients respond and potential implications
S Deitelzweig, E Terasawa, N Atreja… - Current Medical …, 2023 - Taylor & Francis
Objective To assess potential impacts of formulary tier increases of apixaban—an
efficacious oral anticoagulant (OAC) for preventing stroke in patients with atrial fibrillation …
efficacious oral anticoagulant (OAC) for preventing stroke in patients with atrial fibrillation …
Left ventricular hypertrophy and left atrial size are associated with ischemic strokes among non-vitamin K antagonist oral anticoagulant users
Background Ischemic strokes (IS) occurring in patients taking non-vitamin K antagonist oral
anticoagulants (NOACs) are becoming increasingly more frequent. We aimed to determine …
anticoagulants (NOACs) are becoming increasingly more frequent. We aimed to determine …
[HTML][HTML] Nonvitamin K oral anticoagulants with proton pump inhibitor cotherapy ameliorated the risk of upper gastrointestinal bleeding
P Chaiyana, K Techathuvanan, S Sethasine - Scientific Reports, 2023 - nature.com
Proton pump inhibitors (PPIs) can reduce the risk of upper gastrointestinal bleeding (UGIB)
in patients who are taking oral anticoagulants. This study aimed to identify the association …
in patients who are taking oral anticoagulants. This study aimed to identify the association …
[HTML][HTML] Efficacy and safety of various antithrombotic regimens after left atrial appendage occlusion
DV Pevsner, YK Rytova, I Merkulova… - Cardiovascular …, 2022 - cardiovascular.elpub.ru
Aim. To evaluate the efficacy and safety of various antithrombotic regimens after left atrial
appendage occlusion (LAAO) in real clinical practice. Material and methods. This …
appendage occlusion (LAAO) in real clinical practice. Material and methods. This …
A Comparative Study between Conventional and Recent Anticoagulant Therapies in Atrial Fibrillation
EM Hussein, MWM Aboleieneen… - … Egyptian Journal of …, 2022 - ejhm.journals.ekb.eg
Background: Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia,
occurring in 1-2% of the general population. With an aging population, its prevalence is …
occurring in 1-2% of the general population. With an aging population, its prevalence is …
[HTML][HTML] Эффективность и безопасность различных режимов антитромботической терапии после имплантации окклюдера ушка левого предсердия
ДВ Певзнер, ЮК Рытова, ИА Меркулова… - Кардиоваскулярная …, 2022 - cyberleninka.ru
Цель. Оценить эффективность и безопасность различных режимов
антитромботической терапии после имплантации окклюдера ушка левого предсердия …
антитромботической терапии после имплантации окклюдера ушка левого предсердия …